Shares fell 3.4% as investors reacted negatively to signs of cautious outlook and slower-than-expected revenue ramp from signed accounts, despite ongoing channel expansion and AI-driven engagement improvements.

• Revenue showed sequential growth for the second consecutive quarter, supported by channel ecosystem expansion and contracts signed in 2025.
• The company announced a major new channel partner to potentially add access to ~65 million covered lives and 3,500 employer relationships, raising total reach beyond 175 million covered lives.
• Management emphasized the strategic shift towards care delivery to open new revenue streams via outcomes- and claims-based models, leveraging over 100 peer-reviewed clinical studies.
• Proprietary AI engine DarioIQ is actively deployed, with behavioral engagement programs reportedly delivering up to 40% improvement in targeted interventions.
• Despite these positives, investors likely tempered enthusiasm due to cautious commentary on the timing and scale of revenue contribution from new contracts and broader strategic execution risks.